For US Healthcare Professionals Only
For US Healthcare Professionals Only
MAJIC-PV secondary endpoint
As you can see, the separation between the curves happens early on and they remain separated throughout the study. It’s important to remember that inclusion criteria for the study was hydroxyurea resistance. So, from my perspective, these data also tell me that we need to sit up and take notice immediately, because my patients showing signs of hydroxyurea resistance may be at increased risk of major thrombosis.HEAR FROM DR HARRISON ABOUT THE MAJIC-PV STUDY
32P=radiophosphorus 32; AE=adverse event; BAT=best available therapy; CI=confidence interval; CT=computed tomography; EFS=event-free survival; ELN=European LeukemiaNet; Hct=hematocrit; HR=hazard ratio; HU=hydroxyurea; MPN=myeloproliferative neoplasm; MRI=magnetic resonance imaging; PV=polycythemia vera; RESPONSE=Randomized study of Efficacy and Safety in POlycythemia vera with JAK iNhibitor ruxolitinib verSus bEst available care; WBC=white blood cell.
References: 1. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41(19):3534-3544. Supplemental information available at: https://ascopubs.org/doi/suppl/10.1200/JCO.22.01935. 2. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 3. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435. Supplementary appendix available at: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1409002/suppl_file/nejmoa1409002_appendix.pdf.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.